Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...

Benzinga · May 6 20:37

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks After First Tumor Is Treated With Alpha Dart Alone

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone

- Effect seen across both Panc02 and KPC tumor models -

JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks...

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks After First Tumor Is Treated With Alpha Dart Alone

Risk Disclaimer